SERES THERAPEUTICS INC (MCRB) Forecast, Price Target & Analyst Ratings
NASDAQ:MCRB • US81750R2013
9.52 USD
+0.39 (+4.27%)
Last: Mar 5, 2026, 08:05 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for SERES THERAPEUTICS INC (MCRB).
Forecast Snapshot
Consensus Price Target
$21.42
+ 125.00% Upside
Next Earnings Forecast
Release DateMar 11, 2026
PeriodQ4 / 2025
EPS Estimate-$2.15
Revenue Estimate
ChartMill Buy Consensus
77.78%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$21.42
Upside
+ 125.00%
From current price of $9.52 to mean target of $21.42, Based on 9 analyst forecasts
Low
$20.20
Median
$21.42
High
$23.10
Price Target Revisions
1 Month
0.00%
3 Months
31.25%
Price Target Summary
9 analysts have analysed MCRB and the average price target is 21.42 USD. This implies a price increase of 125% is expected in the next year compared to the current price of 9.52.
The average price target has been revised upward by 31.25% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
77.78%
MCRB was analyzed by 9 analysts. The buy percentage consensus is at 78. So analysts seem to be have mildly positive about MCRB.
In the previous month the buy percentage consensus was at a similar level.
MCRB was analyzed by 9 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-09-24 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-05-08 | Chardan Capital | Downgrade | Buy -> Neutral |
| 2025-03-20 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-03-14 | Goldman Sachs | Maintains | Sell -> Sell |
| 2024-11-14 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-11-13 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-10-24 | JP Morgan | Downgrade | Neutral -> Underweight |
| 2024-09-13 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-08-14 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-08-14 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-06-07 | Oppenheimer | Downgrade | Outperform -> Perform |
| 2024-06-07 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-05-09 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-05-08 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-03-06 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-03-06 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-01-16 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2023-11-03 | Goldman Sachs | Maintains | Sell -> Sell |
| 2023-04-28 | Chardan Capital | Maintains | Buy |
| 2023-04-21 | JP Morgan | Initiate | Neutral |
| 2023-03-21 | Canaccord Genuity | Maintains | Buy |
| 2023-03-08 | Chardan Capital | Reiterate | Buy |
| 2023-03-08 | Canaccord Genuity | Maintains | Buy |
| 2023-03-08 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-02-08 | HC Wainwright & Co. | Reiterate | Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateMar 11, 2026
PeriodQ4 / 2025
EPS Estimate-$2.15
Revenue Estimate
Revenue Q2QN/A
EPS Q2Q-7.61%
Number of Analysts5
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
1.25%
EPS (3 Months)
1.25%
Next Earnings Summary
MCRB is expected to report earnings on 3/11/2026. The consensus EPS estimate for the next earnings is -2.15 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 34.505M 22.07% | 33.215M -3.74% | 144.927M 336.33% | 10.929M -100.00% | 128.59M | 272.003K | -100.00% | |||||||
| EBITDA YoY % growth | -62.781M 32.07% | -81.552M -29.90% | -58.546M 28.21% | -242.909M -195.98% | -118.514M -5.75% | -119.267M 38.56% | -81.6M 27.52% | -85.68M -5.00% | -86.7M -1.19% | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -70.384M 29.82% | -88.13M -25.21% | -64.493M 26.82% | -234.172M -178.97% | -124.964M -5.32% | -125.264M 37.70% | -98.45M 16.60% | -72.967M 25.88% | -83.586M -14.55% | -79.05M 5.43% | -79.05M | -79.05M | -79.05M | |
| Operating Margin | -203.98% | -265.33% | -44.50% | -2,142.67% | -97.18% | N/A | -36,194.55% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | -26.20 46.09% | -23.00 12.21% | -14.40 37.39% | -45.91 -225.00% | -20.14 61.54% | -2.18 -7.78% | 0.72 103.73% | -8.85 -1,322.54% | -10.87 -22.81% | 3.60 133.11% | N/A | N/A | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -2.15 -7.61% | -1.79 39.70% | -1.96 13.73% | -1.96 -308.34% | -2.12 1.42% |
| Revenue Q2Q % growth | -100.00% | ||||
| EBITDA Q2Q % growth | -27.54M -17.86% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -20.196M 29.96% | -16.32M 40.08% | -26.52M -6.59% | -27.03M -20.26% | -28.56M -41.41% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
12.91%
EPS Next 5 Year
21.59%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
9.36%
EBIT Next 5 Year
N/A
SERES THERAPEUTICS INC / MCRB Forecast FAQ
What is the price target for MCRB stock?
9 analysts have analysed MCRB and the average price target is 21.42 USD. This implies a price increase of 125% is expected in the next year compared to the current price of 9.52.
What is the next earnings date for MCRB stock?
SERES THERAPEUTICS INC (MCRB) will report earnings on 2026-03-11, after the market close.
What are the consensus estimates for MCRB stock next earnings?
The consensus EPS estimate for the next earnings of SERES THERAPEUTICS INC (MCRB) is -2.15 USD and the consensus revenue estimate is 0 USD.
Can you provide the consensus rating for SERES THERAPEUTICS INC stock?
The consensus rating for SERES THERAPEUTICS INC (MCRB) is 77.7778 / 100 . This indicates that analysts generally have a positive outlook on the stock.